Definium Therapeutics (DFTX) Other Working Capital Changes (2021 - 2026)

Definium Therapeutics (DFTX) has reported Other Working Capital Changes for 6 consecutive years, with -$585000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Working Capital Changes fell 142.39% year-over-year to -$585000.0; the TTM figure through Mar 2026 stood at -$2.1 million (down 134.23% YoY), while the FY2025 annual figure was -$152000.0, down 103.5% from the prior year.
• Other Working Capital Changes retreated to -$585000.0 in Q1 2026 per DFTX's latest filing, from $2.4 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $3.8 million in Q4 2024 and bottomed at -$3.1 million in Q2 2025.
• Historically, Other Working Capital Changes has averaged $224764.7 across 5 years, with a median of -$468000.0 in 2024.
• Annual changes were most pronounced in 2024 — Other Working Capital Changes jumped 1476.85% — and 2025, when it slumped 309.55%.
• Definium Therapeutics' Other Working Capital Changes stood at $2.1 million in 2022, then declined by 26.75% to $1.5 million in 2023, then soared by 147.72% to $3.8 million in 2024, then slumped by 35.93% to $2.4 million in 2025, then sank by 124.0% to -$585000.0 in 2026.
• Business Quant data shows DFTX's Other Working Capital Changes at -$585000.0 in Q1 2026, $2.4 million in Q4 2025, and -$854000.0 in Q3 2025.